 |
|
The Effects of Carbocisplatin and Radiation on Skin Flap Survival
Lee A. Kleiman, MD;
Brian Hasslinger, MD;
Hugh Eddy, PhD;
Charles Suter, PhD;
Cyrus Blanchard, MD;
William Gray, MD
Arch Otolaryngol Head Neck Surg. 1992;118(1):68-73.
Abstract
• Carbocisplatin is used as an inductive chemotherapeutic agent prior to irradiation in the treatment of head and neck cancers. Controversy exists whether carbocisplatin sensitizes normal epithelial tissues, including skin, to radiation. The combined effect of radiation and carbocisplatin on the survival of skin flaps was studied in an experimental model using dorsal flaps in Sprague-Dawley rats. Skin flaps were created 6 weeks after exposure to irradiation and carbocisplatin. Flap survival was assessed 7,14, and 21 days after the flaps were initially created. Exposure of the flaps to irradiation alone, carbocisplatin alone, combined irradiation and carbocisplatin, or combined irradiation and fractionated carbocisplatin did not result in any significant decrease in flap survival when compared with untreated animals.
(Arch Otolaryngol Head Neck Surg. 1992;118:68-73)
Author Affiliations
From the Division of Otorhinolaryngology (Drs Kleiman, Hasslinger, Suter, Blanchard, and Gray), University of Maryland School of Medicine; and the Division of Radiation Research, University of Maryland School of Medicine (Dr Eddy), Baltimore, Md.
Footnotes
Accepted for publication September 3, 1991.
Presented at the 75th Annual Meeting of the Pacific Coast Otoophthalmological Society, Monterey, Calif, June 15-19, 1991.
Reprint requests to the Division of Otolaryngology, University of Maryland Medical Systems, Box 164, N4W79, 22 S Greene St, Baltimore, MD 21201 (Dr Kleiman).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Transforming Growth Factor {beta}1 Improves Wound Healing and Random Flap Survival in Normal and Irradiated Rats
Nall et al.
Arch Otolaryngol Head Neck Surg 1996;122:171-177.
ABSTRACT
|
